Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 11Lymphoid 7Sarcoma 5CNS 3Thoracic 2Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 3510Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Leukemia, Lymphocytic, Chronic, B-Cell 1992Myelodysplastic Syndromes 1412Hematologic Neoplasms 1385Lymphoma 1176Lymphoma, Non-Hodgkin 1079Leukemia, Myelogenous, Chronic, BCR-ABL Positive 863Lymphoma, Follicular 761Multiple Myeloma 739Lymphoma, Mantle-Cell 730Lymphoma, Large B-Cell, Diffuse 714Burkitt Lymphoma 692Lymphoma, B-Cell, Marginal Zone 645Hodgkin Disease 636Recurrence 627Leukemia, Myelomonocytic, Chronic 536Neoplasms 519Lymphoma, Large-Cell, Immunoblastic 451Myeloproliferative Disorders 445Leukemia, Myeloid, Chronic-Phase 437Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 414Congenital Abnormalities 411Waldenstrom Macroglobulinemia 360Blast Crisis 353Leukemia, Myeloid, Accelerated Phase 318Lymphoma, T-Cell, Cutaneous 311Primary Myelofibrosis 297Neoplasms, Plasma Cell 276

Interventions

ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Granuloma, Plasma Cell × Other hematologic neoplasm × Clear all
NCT02465528 2019-12-27

Ceritinib Rare Indications Study in ALK+ Tumors

Novartis

Phase 2 Terminated
22 enrolled 16 charts
CNSLymphoidOther hematologic neoplasmPlasma cell

Glioblastoma, Granuloma, Plasma Cell, Lymphoma, Large-Cell, Anaplastic, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡